Dendritic cell-targeted lentiviral vector development

Lentiviral vectors have been useful in research and for gene therapy because of their ability to stably express genes in a wide variety of target cell-types.  However, lentiviral vectors don’t work well in DCs because they are blocked by SAMHD1.  To overcome this block to DC transduction, we devised HIV-1-based lentiviral vectors that package SIV Vpx resulting in a two-log increase in titer on DCs.  This high efficiency transduction provides a means by which DCs can be used in gene therapy.  In addition, the vectors encode various immunostimulatory genes that induce the DCs to secrete T cell activating cytokines that will increase the strength of the immune response.  Through these studies, we are learning how DCs function and how they can be engineered to stimulate antigen-specific T cells. 

Department of Microbiology

Alexandria Center for Life Science - West Tower

430 East 29th Street
Office Rm. 509, Lab Rm. 524
New York, NY 10016

Nathaniel.Landau@nyulangone.org


Direct Line: (212) 263-9197
Fax: (646) 501-4645

Prof. Nathaniel R. Landau, PhD

 

Professor, Department of Microbiology

 

Member of the Microbial Pathogenesis Program

Full Bio.

  • Twitter Social Icon

©2019 Landau Lab - Biomedical Research Lab at NYU - New York City